Can a Third-Generation ALK Inhibitor Improve Outcomes in NSCLC?

In this phase II trial, researchers tested the efficacy of lorlatinib in six expansion cohorts of NSCLC patients based on ALK mutation status and prior treatment.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news